EUCTR2005-003357-27-DE进行中（未招募）不适用
A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy - POINT II
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Men or women, 18 years of age or older
- •· NSCLC has been histologically or cytologically confirmed
- •· Has relapsed or refractory locally advanced (Stage IIIb) or metastatic (Stage IV) NSCLC (see Attachment 3 for tumor nodule metastasis [TNM] staging)
- •· Failed one prior line of systemic antineoplastic therapy for Stage IIIb/IV NSCLC (one additional prior line allowed if given as neoadjuvant, or adjuvant therapy to tumor resection)
- •· Subject must have documented PD since previous systemic antineoplastic therapy
- •· Has measurable disease per RECIST criteria (Attachment 4)
- •· Has an ECOG performance status score of 0 or 1 (Attachment 5)
- •· Has a life expectancy greater than 3 months
- •· Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening
- •· Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to and able to comply with the protocol requirements and participate in the study before any study-related procedure not part of normal medical care is conducted.
- •· In countries where health authorities have approved the pharmacogenomic and protein testing, subjects (or their legally acceptable representatives) must have signed an informed consent for testing indicating, that they agree to participate in the genetic part and protein testing part of the study; participation in the genetic and protein testing component is mandatory for testing described in Section 9.4, but optional for future research.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· Has peripheral neuropathy of Grade 2 or greater intensity, as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE Version 3.0)
- •· Previous treatment with VELCADE or Alimta
- •· Has received 2 or more prior lines of antineoplastic therapies for Stage IIIb/IV NSCLC
- •· Any prior systemic antineoplastic therapy for NSCLC (i.e., prior chemotherapy, radiation therapy, prior monoclonal antibodies or any investigational drug or any major surgery) within 4 weeks before randomization
- •· Has had significant weight loss (documented =10% body weight in the 6 weeks before randomization)
- •· Inadequate organ function at the screening visit as defined by the following laboratory values:
- •Platelet count =100 x 10E9/L
- •Hemoglobin =8.0 g/dL (80 g/L)
- •Absolute neutrophil count (ANC) =1.5 x 10E9/L
- •AST =3 times the upper limit of the normal range (ULN) or >5 times the ULN for subjects with liver metastases
- •ALT =3 times ULN
- •Calculated creatinine clearance =45 mL/min
- •Total bilirubin =1.5 times ULN
- •· Myocardial infarction within 6 months before randomization or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. (Attachment 6)
- •· Central nervous system metastasis or brain metastases that have not been completely resected or completely eliminated by radiation therapy and/or chemotherapy, or clinical or radiographic evidence that they have recurred. Subjects with a history of brain metastases are required to have had a brain computed tomography (CT) or magnetic resonance imaging (MRI) scan conducted within 1 month of enrollment to verify the continuing absence of brain metastases.
- •· Uncontrolled pleural effusion (defined as more than 2 pleuracentesis within 4 weeks of the randomization)
- •· Active systemic infection requiring treatment
- •· Inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) for a 5-day period (8-day period for long-acting agents, such as piroxicam)
- •· Unable or unwilling to take corticosteroids
- •· Other malignancy within the past 5 years. Exceptions for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ or International Federation of Gynecology and Obstetrics (FIGO) Stage 1 carcinoma of the cervix
- •· History of allergic reaction attributable to compounds containing boron or mannitol
- •· Is pregnant or breast-feeding
- •· Currently enrolled in another clinical research study or has received an investigational agent for any reason within 4 weeks before randomization.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter Study of Alimta pemetrexed Plus VELCADE bortezomib or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy - POINT IIAdvanced or metastatic NSCLCMedDRA version: 6.1Level: PTClassification code 10061873EUCTR2005-003357-27-ITJANSSEN-CILAG INTERNATIONAL NV135
进行中（未招募）
不适用
A study of the safety, efficacy, and tolerability of combination treatment of setrobuvir, danoprevir, ritonavir, and Copegus® with or without mericitabine in patients infected with the Hepatitis C virus who never received treatment beforeEUCTR2012-000638-21-PLF. Hoffmann-La Roche Ltd110
进行中（未招募）
不适用
A study of the safety, efficacy, and tolerability of combination treatment of setrobuvir, danoprevir, ritonavir, and Copegus® with or without mericitabine in patients infected with the Hepatitis C virus who never received treatment before.Chronic Hepatitis C (genotype 1)MedDRA version: 16.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000638-21-DEF. Hoffmann-La Roche Ltd110
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a chemotherapy drug, called vorinostat, will work in patients with recurrent or unsuccessfully treated Cutaneous T-Cell Lymphoma.Treatment of subjects with previously treated cutaneous T-cell lymphomaMedDRA version: 22.0Level: PTClassification code 10011679Term: Cutaneous T-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004766-17-DKKyowa Kirin Pharmaceutical Development, Inc.317
已完成
3 期
Study of KW-0761 Versus Vorinostat In Relapsed/Refractory CTCL.JPRN-jRCT2080222561Kyowa Kirin Pharmaceutical Development, Inc.372